ProNeuro Centrum Medyczne

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

  NCT07673744· Phase 2· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Source

• Active, not recruiting

  A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT07074886· Phase 2· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Active, not recruiting

  A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

  2022-501622-37-00· Phase 3· Source

• Recruiting

  Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

  NCT05877963· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis2 recruiting
• Myasthenia gravis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

  NCT07667322· Phase 1· Source

• Active, not recruiting

  A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)

  2023-506183-13-00· Phase 2· Source

• Completed

  A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

  NCT04836559· Phase 2· Source